SCHOTT Pharma AG & Co KgaA
F:1SXP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.28
30.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
SCHOTT Pharma AG & Co KgaA
SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe.
SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.
SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe.
SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.
Revenue Growth: SCHOTT Pharma reported third quarter revenue of EUR 256 million, up 3% year-on-year at constant currencies, despite a strong prior-year comparison.
Profitability: EBITDA reached EUR 83 million, increasing by 11% year-on-year, with a record EBITDA margin of 31.7% driven by a higher share of high-value solutions and efficiency gains.
Guidance Update: Full-year organic revenue growth guidance was specified at around 6%, with the EBITDA margin outlook raised to about 28%.
High-Value Solutions Expansion: HVS now represents 60% of Q3 revenues, up 5 percentage points year-on-year, and management raised its ambition for HVS revenue share to above 55% for the full year.
Segment Performance: Drug Containment Solutions (DCS) led growth with an 8% year-on-year increase at constant currencies, while Drug Delivery Systems (DDS) showed resilience despite a slight decline versus a strong prior year.
Sustained Demand: Management highlighted continued strong demand for specialty vials and sterile cartridges, especially for biologics and GLP-1 therapies.
Efficiency Gains: Significant double-digit million euro efficiency savings were achieved, with more measures planned.
No Order Cancellations: Management confirmed there have been no order cancellations, and the U.S. market posted strong double-digit revenue growth.
